Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors

Mostrar otras versiones (1)

INTRODUCTION: There is controversy concerning the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II type-I receptor blockers (ARB) for treating hypertensive patients with Covid-19. It has been hypothesized that these drugs might increase the risk of severe Covid-19, but some a...

Descripción completa

Detalles Bibliográficos
Autores principales: Golpe, Rafael, Pérez-de-Llano, Luis A., Dacal, David, Guerrero-Sande, Hector, Pombo-Vide, Beatriz, Ventura-Valcárcel, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier España, S.L.U. 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316050/
https://www.ncbi.nlm.nih.gov/pubmed/32651067
http://dx.doi.org/10.1016/j.medcli.2020.06.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316050/
https://www.ncbi.nlm.nih.gov/pubmed/32651067
http://dx.doi.org/10.1016/j.medcli.2020.06.013

Ejemplares similares